GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AXIM Biotechnologies Inc (OTCPK:AXIM) » Definitions » Shares Outstanding (EOP)

AXIM (AXIM Biotechnologies) Shares Outstanding (EOP) : 294.46 Mil (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is AXIM Biotechnologies Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. AXIM Biotechnologies's shares outstanding for the quarter that ended in Jun. 2024 was 294.46 Mil.

AXIM Biotechnologies's quarterly shares outstanding increased from Mar. 2024 (278.43 Mil) to Jun. 2024 (294.46 Mil). It means AXIM Biotechnologies issued new shares from Mar. 2024 to Jun. 2024 .

AXIM Biotechnologies's annual shares outstanding increased from Dec. 2022 (192.44 Mil) to Dec. 2023 (245.93 Mil). It means AXIM Biotechnologies issued new shares from Dec. 2022 to Dec. 2023 .


AXIM Biotechnologies Shares Outstanding (EOP) Historical Data

The historical data trend for AXIM Biotechnologies's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AXIM Biotechnologies Shares Outstanding (EOP) Chart

AXIM Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.86 125.33 138.10 192.44 245.93

AXIM Biotechnologies Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 227.65 237.65 245.93 278.43 294.46

Competitive Comparison of AXIM Biotechnologies's Shares Outstanding (EOP)

For the Biotechnology subindustry, AXIM Biotechnologies's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AXIM Biotechnologies's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's Shares Outstanding (EOP) falls into.



AXIM Biotechnologies Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


AXIM Biotechnologies  (OTCPK:AXIM) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


AXIM Biotechnologies Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of AXIM Biotechnologies's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


AXIM Biotechnologies Business Description

Traded in Other Exchanges
N/A
Address
6191 Cornerstone Court, E, Suite 114, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.
Executives
Kurt Phinney officer: Chief Operating Officer 6914 MAGELLAN WAY, SARASOTA FL 34243
Peter O'rourke director C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001
Catalina Valencia 10 percent owner 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Glycodots, Llc 10 percent owner 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Juniper & Ivy Corp 10 percent owner 5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007
Huemoeller John Walter Ii director 305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960
Blake Schroeder director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert L Cunningham director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Timothy Richard Scott director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert Malasek officer: CFO PO BOX 235472, ENCINITAS CA 92023
Lekhram Changoer 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Medical Marijuana, Inc. 10 percent owner 12255 CROSTHWAITE CIRCLE, POWAY CA 92064
Van Damme Philip A 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Foundation Sanammad 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
George Anastassov 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022

AXIM Biotechnologies Headlines

From GuruFocus

AXIM Biotechnologies CEO Issues Letter to Shareholders

By GuruFocusNews GuruFocusNews 04-19-2022